Galectin Therapeutics Inc... (GALT)
NASDAQ: GALT
· Real-Time Price · USD
4.13
0.56 (15.69%)
At close: Aug 18, 2025, 2:47 PM
Galectin Therapeutics Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -45.19M | -47.05M | -45.08M | -44.28M | -41.03M | -41.07M | -41.7M | -39.87M | -40.37M | -38.78M | -35.36M | -35.29M | -34.12M | -30.53M | -31.16M | -28.58M | -26.25M |
Depreciation & Amortization | 38K | 37K | 36K | 35K | 10K | 33K | 32K | 31K | 54K | 32K | 35K | 38K | 41K | 41K | 39K | 39K | 37K |
Stock-Based Compensation | 2.31M | 2.45M | 2.35M | 2.42M | 2.2M | 2.26M | 2.44M | 2.54M | 2.67M | 2.87M | 2.84M | 2.75M | 2.68M | 2.08M | 1.99M | 1.81M | 1.62M |
Other Working Capital | 1.41M | 2.4M | 1.41M | 2.98M | 2.5M | 2.01M | 1.65M | 1.23M | 916K | 724K | 360K | 288K | 141K | 123K | 286K | -1.08M | -1.18M |
Other Non-Cash Items | 1.39M | 2.47M | 4.08M | 1.75M | 1.78M | 1.62M | 1.62M | 1.28M | 915K | -147K | -208K | -538K | -84K | 87K | 314K | 323K | 87K |
Deferred Income Tax | n/a | n/a | n/a | n/a | -490K | -490K | -490K | -490K | n/a | n/a | n/a | 166K | 166K | 166K | 166K | n/a | n/a |
Change in Working Capital | 2.63M | 326K | 4.93M | 7.29M | 3.25M | 4.68M | 2.59M | 298K | 2.92M | 4.97M | 1.93M | 5.46M | 5.35M | 3.85M | 5.88M | 425K | 1.89M |
Operating Cash Flow | -37.35M | -41.77M | -33.68M | -32.78M | -34.28M | -32.97M | -35.5M | -36.21M | -33.81M | -31.06M | -30.77M | -27.42M | -25.97M | -24.31M | -22.77M | -25.98M | -22.61M |
Capital Expenditures | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Investing Acitivies | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Investing Cash Flow | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Debt Repayment | 10M | 20M | 30M | 30M | 30M | 30M | 30M | 30M | 20M | 10M | 10M | 20M | 20M | 20M | 10M | n/a | n/a |
Common Stock Repurchased | 568K | 845K | 1.22M | 651K | 651K | 374K | 899K | 899K | 899K | 899K | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | -80K | -18K | -18K | n/a | n/a | n/a | -48K | -48K | -48K | -97K | -49K | -49K | -49K | -67K | -204K | -204K | -204K |
Other Financial Acitivies | 11.24M | 11.24M | 10.39M | 10.41M | 10.03M | 10.03M | 10.08M | 48K | 48K | 48K | n/a | n/a | 10M | 10.07M | 10.2M | 10.2M | 204K |
Financial Cash Flow | 21.23M | 31.23M | 40.38M | 40.41M | 40.03M | 40.03M | 40.03M | 30M | 20M | 10M | 10M | 20M | 36.81M | 36.81M | 26.82M | 16.82M | 44K |
Net Cash Flow | -16.12M | -10.54M | 6.7M | 7.63M | 5.56M | 7.07M | 4.53M | -6.21M | -13.61M | -21.06M | -20.77M | -7.42M | 10.85M | 12.51M | 4.04M | -9.17M | -22.57M |
Free Cash Flow | -37.35M | -41.77M | -33.68M | -32.78M | -34.28M | -32.97M | -35.5M | -36.21M | -33.81M | -31.06M | -30.77M | -27.42M | -25.97M | -24.31M | -22.77M | -25.98M | -22.61M |